Related Experiment Video
Updated: Jun 8, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
BRAF inhibitor unveils its potential against advanced melanoma
Adina Vultur1, Jessie Villanueva, Meenhard Herlyn
1The Wistar Institute, Philadelphia, PA 19104, USA.
Abstract:
Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.
Insights
Targeted therapy for advanced melanoma shows promise. Recent studies validate PLX4032, a BRAF kinase inhibitor, for treating melanomas with BRAF-activating mutations.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Advanced metastatic melanoma often exhibits unresponsiveness to conventional therapies.
- BRAF-activating mutations are identified in approximately 50% of human melanomas, presenting a key therapeutic target.
Discussion:
- Two recent publications highlight the efficacy of the mutant BRAF kinase inhibitor PLX4032.
- These studies validate the concept of oncogene-targeted therapy for melanoma treatment.
Key Insights:
- PLX4032 effectively targets mutant BRAF kinases in melanoma.
- The findings support the development of precision medicine approaches for melanoma.
Outlook:
- Further research into BRAF inhibitors like PLX4032 is warranted for advanced melanoma.
- Oncogene-targeted therapy represents a significant advancement in melanoma treatment strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

